L-dopa-induced respiratory disturbance in Parkinson's disease suppressed by tiapride.
L-dopa treatment provoked an irregular breathing pattern and dyspnea in a patient with Parkinson's disease. This side effect strongly limited adequate antiparkinsonian treatment with L-dopa. Simultaneous administration of L-dopa and tiapride resulted in improvement of parkinsonian symptoms and suppressed the respiratory side effect completely.
D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D012120:Respiration Disorders / Q000139:chemically induced* / Q000188:drug therapy; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use*
D001549:Benzamides; D007980:Levodopa; D013976:Tiapamil Hydrochloride